Treatment for Yeast Infections
For uncomplicated vaginal yeast infections (vulvovaginal candidiasis), a single 150-mg oral dose of fluconazole or topical antifungal agents are equally effective and recommended as first-line therapy. 1, 2
First-Line Treatment Options
Oral Therapy
- Fluconazole 150 mg single oral dose
Topical Therapy Options
- Clotrimazole vaginal cream/tablets (2% cream for 3 days) 5
- Miconazole vaginal suppositories/cream
- Nystatin vaginal tablets
Both treatment approaches show similar efficacy rates, with clinical cure or improvement in 94% of fluconazole-treated patients and 97% of clotrimazole-treated patients at 14-day evaluation 6.
Treatment for Severe Acute Vulvovaginal Candidiasis
Treatment for Non-albicans Candida Species (e.g., C. glabrata)
For C. glabrata infections unresponsive to oral azoles:
- Topical intravaginal boric acid 600 mg daily for 14 days 1, 2
- Nystatin intravaginal suppositories 100,000 units daily for 14 days 1, 2
- Topical 17% flucytosine cream alone or with 3% AmB cream daily for 14 days 1, 2
Treatment for Recurrent Vulvovaginal Candidiasis
- Initial treatment: 10-14 days of induction therapy with topical agent or oral fluconazole
- Followed by maintenance therapy: Fluconazole 150 mg weekly for 6 months 1, 2
Clinical Considerations
- Patients with a history of recurrent vaginitis are significantly less likely to respond to treatment (p<0.001) 6
- At 35-day evaluation, approximately 75% of patients remain clinically cured with either oral fluconazole or topical treatment 6
- Patient preference often favors oral administration over local therapy 7
Contraindications for Fluconazole
Do not use fluconazole if the patient:
- Takes quinidine, erythromycin, or pimozide
- Has a known allergy to fluconazole or its ingredients
- Is pregnant or breastfeeding (not recommended) 4, 7
Treatment Selection Factors
- Severity of infection
- History of recurrent infections
- Suspected or confirmed Candida species
- Patient preference
- Pregnancy status
Oral fluconazole provides a convenient single-dose option with high efficacy rates comparable to traditional topical treatments, making it an excellent first-line choice for uncomplicated vaginal yeast infections.